Literature DB >> 29769907

Vaccine vigilance in Canada: Is it as robust as it could be?

P Duclos1.   

Abstract

Canada has been known to have one of the better vaccine safety surveillance capacities in the world, but in the early 2000s, it was noted there was still room for improvement. How has Canada done over the last decade and is there more to be done? Canada has done well. First, there has been significant progress made by the Vaccine Vigilance Working Group to enhance the passive vaccine safety monitoring system and address potential issues arising from the review of surveillance data and cases or clusters of concern. Second, there has been an increased investigative capacity for clusters of adverse events and other vaccine safety issues, including an assessment and referral system for individuals with adverse events following immunizations (AEFIs). Third, the use of the Brighton Collaboration definitions and other international standards has facilitated international collaboration and represents the best standard of practice. Despite all these improvements, however, there is more that could be done. The sensitivity of Canada's passive surveillance system still varies from one province and territory to another. The timeliness of the data exchange flow could improve. The AEFI Signal Response Protocol, which identifies the processes and required actions for timely management of any newly detected or emerging vaccine safety signals, is a critical piece of a robust vaccine safety system but it is still in the making. It is commendable that Canada has decided to expand its focus on evaluation research from influenza vaccines to vaccine-preventable diseases more broadly, with the establishment of the Canadian Immunization Research Network (CIRN). CIRN's newly developed Provincial Collaborative Network and the move toward record linkages is excellent. These new investments are welcome in light of the rich vaccine development pipeline, the increased pool of available vaccines, and the growing set of technologies for vaccines production, delivery, and safety monitoring. What would round this all out would be a stronger capacity to monitor the implementation of vaccination programs and vaccine coverage, and better documentation of the reduction of the disease burden attributable to vaccination programs. Canada's investment in vaccines for the health of all deserves no less.

Entities:  

Year:  2014        PMID: 29769907      PMCID: PMC5868612          DOI: 10.14745/ccdr.v40is3a01

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  10 in total

Review 1.  Vaccine adverse events in the new millennium: is there reason for concern?

Authors:  B J Ward
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

2.  Reinforcing surveillance for vaccine-associated adverse events: The Advisory Committee on Causality Assessment.

Authors:  R Pless; P Duclos
Journal:  Can J Infect Dis       Date:  1996-03

3.  Canadian Paediatric Surveillance Program evaluation: An excellent report card.

Authors:  D Grenier; J Doherty; D Macdonald; J Scott; G Delage; A Medaglia; Ma Davis
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

4.  Immunization safety: A global priority - a major contribution of Canada's international immunization efforts.

Authors:  P Duclos; Y Bergevin
Journal:  Paediatr Child Health       Date:  2000-10       Impact factor: 2.253

5.  The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases.

Authors:  J A Bettinger; S A Halperin; W Vaudry; B J Law; D W Scheifele
Journal:  Can Commun Dis Rep       Date:  2014-12-04

6.  Canada's Vaccine Vigilance Working Group.

Authors:  N Ahmadipour; E Toth; B J Law
Journal:  Can Commun Dis Rep       Date:  2014-12-04

7.  Decline in mortality with the Belize Integrated Patient-Centred Country Wide Health Information System (BHIS) with embedded program management.

Authors:  Michael Graven; Peter Allen; Ian Smith; Noni E MacDonald
Journal:  Int J Med Inform       Date:  2013-07-06       Impact factor: 4.046

8.  Behind the scenes in public health: Adverse events following immunization (AEFI) signal investigation in British Columbia.

Authors:  L MacDonald; M Naus
Journal:  Can Commun Dis Rep       Date:  2014-12-04

9.  Analyzing and strengthening the vaccine safety program in Manitoba.

Authors:  J M Montalban; C Ogbuneke; T Hilderman
Journal:  Can Commun Dis Rep       Date:  2014-12-04

10.  Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012.

Authors:  B J Law; J Laflèche; N Ahmadipour; H Anyoti
Journal:  Can Commun Dis Rep       Date:  2014-12-04
  10 in total
  2 in total

1.  Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.

Authors:  Natalia Abraham; Sarah Spruin; Tanya Rossi; Bruce Fireman; Joseline Zafack; Christine Blaser; Amanda Shaw; Kimberley Hutchings; Susanna Ogunnaike-Cooke
Journal:  Vaccine       Date:  2022-05-25       Impact factor: 4.169

2.  Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013-2016.

Authors:  N Ahmadipour; K Watkins; M Fréchette; C Coulby; H Anyoti; K Johnson
Journal:  Can Commun Dis Rep       Date:  2018-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.